Pemafibrate is primarily used in the treatment of dyslipidemia, particularly for patients with high triglyceride levels and low HDL cholesterol. It works by activating PPARα receptors, which helps in reducing triglyceride production and increasing the breakdown of fatty acids in the liver. This makes it effective in managing lipid abnormalities and reducing the risk of cardiovascular diseases. Additionally, it is often prescribed for patients who do not respond adequately to other lipid-lowering medications. Its targeted action on lipid metabolism also makes it beneficial for individuals with metabolic syndrome or type 2 diabetes, where abnormal lipid profiles are common. Furthermore, it may be used in patients with non-alcoholic fatty liver disease (NAFLD) to help improve liver function.